Global Orphan Drug Designation Status Database Market Clinical Pipeline Trials Insight 2023

“Global Orphan Drug Market & Clinical Pipeline Insight 2023” Report Highlights:

• Clinical Insight on 800 Orphan Drugs
• Patent Insight, Orphan Designated Indication & Region/Country
• Marketed Orphan Drugs: More Than 300
• Maximum Orphan Designated Drugs in Phase-II: More Than 200
• Global Orphan Drug Designation Criteria
• FDA & EMA Guidelines

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Global Orphan Drug Market Overview
1.1 Market Overview
1.2 Global Orphan Drug Clinical Pipeline Overview

2. Global Orphan Drug Designation Criteria
2.1 US Food and Drug Administration (US FDA)
2.2 European Medicines Agency (EMA)
2.3 Japan
2.4 Taiwan
2.5 Korean Food and Drug Administration (KFDA)
2.6 Australia

Global Orphan Drug Clinical Pipeline by Company, Indication & Phase

3. Orphan Drug Development Phase: Unknown
3.1 Overview
3.2 Clinical Pipeline Insight

4. Orphan Drug Development Phase: Research
4.1 Overview
4.2 Clinical Pipeline Insight

5. Orphan Drug Development Phase: Preclinical
5.1 Overview
5.2 Clinical Pipeline Insight

6. Orphan Drug Development Phase: Clinical
6.1 Overview
6.2 Clinical Pipeline Insight

7. Orphan Drug Development Phase: Phase-0
7.1 Overview
7.2 Clinical Pipeline Insight

8. Orphan Drug Development Phase: Phase - I
8.1 Overview
8.2 Clinical Pipeline Insight

9. Orphan Drug Development Phase: Phase - I/II
9.1 Overview
9.2 Clinical Pipeline Insight

10. Orphan Drug Development Phase: Phase - II
10.1 Overview
10.2 Clinical Pipeline Insight

11. Orphan Drug Development Phase: Phase - II/III
11.1 Overview
11.2 Clinical Pipeline Insight

12. Orphan Drug Development Phase: Phase - III
12.1 Overview
12.2 Clinical Pipeline Insight

13. Orphan Drug Development Phase: Preregistration
13.1 Overview
13.2 Clinical Pipeline Insight

14. Orphan Drug Development Phase: Registered
14.1 Overview
14.2 Clinical Pipeline Insight

15. Marketed Orphan Drug Clinical Insight by Company, Indication & Phase
15.1 Overview
15.2 Clinical Pipeline Insight

16. Discontinued & Suspended Orphan Drugs in Clinical Pipeline by Company, Indication & Phase
16.1 No Development Reported
16.2 Discontinued
16.3 Preregistration Submission Withdrawal
16.4 Marketed Withdrawal
16.5 Suspended

17. Competitive Landscape
17.1 AOP Orphan
17.2 Agenus
17.3 Alexion
17.4 Bristol Myers Squibb
17.5 Biogen Idec
17.6 Celgene
17.7 Eli Lilly
17.8 Genethon
17.9 Genzyme Corporation
17.10 Glaxosmithkline
17.11 Merck
17.12 Novartis Pharmaceuticals
17.13 Orphan Europe
17.14 Pfizer
17.15 Prosensa
17.16 Rare Disease Therapeutics
17.17 Roche
17.18 Sanofi
17.19 Shire
17.20 Teva Pharmaceutical

For Report Sample Contact: neeraj@kuickresearch.co or +91-11-47067990

Figure 1-1: Global Orphan Drugs Market Value (US$ Billion), 2016-2023
Figure 1-2: US - Orphan Drugs Market Value (US$ Billion), 2016-2023
Figure 1-3: Europe - Orphan Drugs Market Value (US$ Billion), 2016-2023
Figure 1-4: Asia* - Orphan Drugs Market Value (US$ Billion), 2016-2023
Figure 1-5: Global - Orphan Drug Clinical Pipeline by Phase (%), 2016 till 2023
Figure 1-6: Global - Orphan Drug Clinical Pipeline by Phase (Numbers), 2016 till 2023
Figure 1-7: Global - Orphan Drug Clinical Pipeline by Phase (%), 2016 till 2023
Figure 1-8: Global - Orphan Drug Clinical Pipeline by Phase (Numbers), 2016 till 2023
Figure 17-1: AOP Orphan
Figure 17-2: Agenus Pipeline
Figure 17-3: Genethon Drug Pipeline
Figure 17-4: Genzyme Drug Pipeline
Figure 17-5: Orphan Europe Pipeline
Figure 17-6: Prosensa Drug Pipeline
Figure 17-7: Shire Drug Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.